Dr. Connie Tong

Cooley advised Avenzo Therapeutics, a clinical-stage biotechnology company developing next-generation oncology therapies, on its exclusive license agreement with Duality Biotherapeutics (DualityBio), pursuant to which Avenzo will develop, manufacture and commercialize AVZO-1418/DB-1418– a potential best-in-class epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 3 (HER3) bispecific antibody-drug conjugate (ADC) – globally (excluding Greater China). 

Cooley advised Neurocrine Biosciences on its strategic partnership agreement with Takeda to develop and commercialize potential therapies in Takeda’s early- to mid-stage pipeline for psychiatric disorders. The partnership will enhance Neurocrine’s growing pipeline of treatments and strengthen the company’s position as a leading neuroscience-focused biopharmaceutical company.

Neurocrine will develop and commercialize all pipeline compounds included in the collaboration. Under the terms of the agreement, Neurocrine will pay Takeda $120 million in upfront cash and up to $495 million in development milestones, $1.4 billion in commercial milestones and double-digit royalties on net sales.